PCSK9 and LDLR Interaction

Primary Molecular Target: LDL Receptor

• The American College of Cardiology and European Heart Journal suggest that PCSK9's principal interaction is with the LDLR, where it functions as a secreted protein that promotes receptor degradation within the liver 1, 2, 3

Clinical Relevance of PCSK9-LDLR Interaction

• Individuals with PCSK9 loss-of-function mutations have increased numbers of LDL receptors on hepatocyte surfaces, promoting robust LDL-cholesterol clearance and lifelong cardiovascular protection, as noted by the American College of Cardiology 4

Complementary Interactions with Other Therapies

• The European Heart Journal states that statins increase LDLR expression through upregulation via the SREBP2 pathway, creating more targets for PCSK9 binding but also more receptors for LDL clearance 2, 3
• The European Heart Journal also notes that the modes of action of PCSK9 inhibitors, statins, and ezetimibe are complementary, with PCSK9 inhibition preventing LDLR degradation while statins increase LDLR expression 2, 3